“The greatest opportunity at Teva is our innovative pipeline. We’re really leaning in on our innovative pipeline as an integral part of our pivot to growth strategy.”
This is the ambitious vision of Dr Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer at Teva Pharmaceuticals.
He speaks about the company’s strategic transformation from generics powerhouse to innovative biopharmaceutical leader - including how strategic partnerships and a matrix organisational approach are driving Teva’s remarkable 10 consecutive quarters of growth.
He shares best practices on leveraging generics expertise for innovation, building successful partnerships across multiple therapeutic areas, and creating synergies between different business portfolios.